On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
If preliminary results were correct, simufilam could be the long-sought-after cure for dementia, the Holy Grail of ...
A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The ...
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal ...
Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...
In ‘Doctored’, Charles Piller, a science journalist, details how groupthink and dishonesty steered Alzheimer’s research off ...
CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ...
The results indicated that simufilam failed to meet each of the ... If you suffered a loss in Cassava Sciences, Inc. during the relevant time frame, you have until February 10, 2025 to request ...
British Columbia is home to a thriving life sciences sector, with over 2,000 companies employing more than 20,000 people across the province. Funding will help adMare BioInnovations create a 30,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback